Pacylex Pharmaceuticals Explores N-myristoyltransferase Inhibitors as Promising ADC Payloads for Cancer Treatment

Pharmaceutical researchers at Pacylex Pharmaceuticals are presenting groundbreaking data on N-myristoyltransferase inhibitors (NMTis) as potential payloads for antibody drug conjugates (ADCs), signaling a potential breakthrough in cancer treatment strategies. During the 2nd Annual ADC Payload Summit in Boston, CEO Michael Weickert will discuss how their lead compound, zelenirstat, could revolutionize cancer therapy across multiple tumor types.

The company's research highlights a significant limitation in current ADC development: the scarcity of effective payloads for killing cancer cells. NMTis represent a novel approach, demonstrating the ability to simultaneously disrupt multiple critical processes necessary for cancer cell survival. Preliminary studies show these inhibitors can regress solid tumor cancers in animal models when used as ADC payloads.

Zelenirstat, Pacylex's first-in-class myristoylation inhibitor, has shown remarkable potential in clinical studies. Phase 1 trials involving 24 patients with refractory lymphoma and solid tumors revealed no dose-limiting toxicities. Notably, patients receiving the recommended Phase 2 dose exhibited significantly improved progression-free and overall survival, with 57% experiencing stable disease for 6-16 months across different cancer types.

The company's extensive portfolio includes 503 NMTis, with 28 compounds demonstrating potent activity against human NMT1. Zelenirstat specifically targets critical cellular mechanisms, including inhibiting myristoylation required for assembling and functioning key molecular complexes like B-cell receptors and blocking respiratory Complex I formation in cancer cell mitochondria.

One particularly promising result emerged from a Phase 2a study where a diffuse large B-cell lymphoma patient achieved a partial response. Currently, the company is conducting studies in acute myeloid leukemia patients, further exploring the therapeutic potential of their NMTi approach.

Weickert emphasized the company's commitment to exploring these inhibitors, noting a strong correlation between genes predicting sensitivity to zelenirstat and ADC targets. This suggests NMTis could be particularly effective in targeting specific cancer cell populations, potentially opening new avenues for personalized cancer treatment.

The research represents a significant step forward in cancer therapeutics, offering hope for more precise and effective treatment strategies across multiple cancer types. By targeting fundamental cellular processes critical to cancer cell survival, NMTis could provide a versatile approach to combating diverse malignancies.